Russian exit tax obligations affect pharma companies leaving Russia. Key steps include valuation, FTS filing, and payment. Make an enquiry.
For a pharmaceutical company withdrawing from the Russian market, exit tax obligations on departure from Russia typically arise at the moment of deregistration, liquidation of a Russian subsidiary, or cessation of a permanent establishment — and the procedural sequence is more compressed than most in-house counsel anticipate.
Under Russian tax legislation, the core procedural steps are as follows. First, the entity must determine the tax base: this requires a formal valuation of Russian-sited assets — including intellectual property licences, marketing authorisations, and inventory — as at the date of departure. For pharmaceutical companies, marketing authorisations and registration certificates registered with the Ministry of Health carry value that the Federal Tax Service increasingly scrutinises on exit. Second, the entity files a final tax return with its registered Federal Tax Service inspectorate, typically within the statutory period following the triggering event. Third, any exit tax liability assessed must be settled before the Federal Tax Service will release the company from the tax register. Failure to do so routinely results in the inspectorate blocking deregistration.
In practice, the valuation stage presents the most significant risk for pharmaceutical companies. Assets that are straightforward to value in other sectors — equipment, receivables — are joined in pharma by sector-specific intangibles whose fair value is contested. Transfer pricing methodology typically governs how those intangibles are priced, and the Federal Tax Service has demonstrated, in recent years, a pattern of challenging valuations on exit that it would not have queried during the operational phase. Tax controversy arising at this stage can delay departure by six months or longer.
For in-house counsel managing a Russian pharmaceutical subsidiary through an exit process, early engagement with Russian tax counsel before any restructuring steps are taken is the operationally sound approach. The procedural clock — and the FTS's scrutiny window — begins earlier than the formal deregistration filing.
For a structured review of your company's exit tax position under Russian law, make an enquiry: info@vetrovpartners.com | .
Further reading on related questions: Court practice shifts on exit tax obligations in Russia and Key risk points in exit tax obligations on departure from Russia.
On the broader Tax Controversy practice: Tax Controversy — Vetrov & Partners.
— Kristina Kornouhova Senior Lawyer, Practice Lead — Tax & Antitrust, Vetrov & Partners vetrovpartners.com/kornouhova/
Kristina Kornouhova heads the firm's tax controversy and antitrust practices. She advises Russian and foreign companies facing Federal Tax Service audits, transfer-pricing disputes, and FAS Russia proceedings. Her work spans pre-litigation tax structuring, voluntary disclosure coordination, and market-definition analyses in antitrust investigations.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry